Concepts (120)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Central Nervous System Neoplasms | 9 | 2022 | 908 | 2.550 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 4 | 2022 | 493 | 1.420 |
Why?
|
| Brain Neoplasms | 16 | 2024 | 8953 | 1.310 |
Why?
|
| Glioma | 10 | 2024 | 3414 | 1.130 |
Why?
|
| Germinoma | 3 | 2022 | 132 | 1.020 |
Why?
|
| Astrocytoma | 1 | 2023 | 775 | 0.610 |
Why?
|
| Ependymoma | 1 | 2021 | 319 | 0.600 |
Why?
|
| Pyrimidinones | 1 | 2020 | 383 | 0.590 |
Why?
|
| Hemodiafiltration | 1 | 2016 | 18 | 0.560 |
Why?
|
| Cranial Irradiation | 1 | 2019 | 391 | 0.550 |
Why?
|
| Testicular Neoplasms | 1 | 2022 | 800 | 0.540 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2021 | 9269 | 0.530 |
Why?
|
| Ifosfamide | 1 | 2016 | 232 | 0.520 |
Why?
|
| Pyridones | 1 | 2020 | 787 | 0.490 |
Why?
|
| Cerebellar Neoplasms | 1 | 2019 | 585 | 0.480 |
Why?
|
| Medulloblastoma | 1 | 2019 | 677 | 0.460 |
Why?
|
| Salvage Therapy | 1 | 2020 | 1265 | 0.440 |
Why?
|
| Hemangioma, Capillary | 1 | 2013 | 62 | 0.420 |
Why?
|
| Paraneoplastic Cerebellar Degeneration | 1 | 2012 | 13 | 0.410 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2016 | 619 | 0.410 |
Why?
|
| Neuroblastoma | 2 | 2021 | 1252 | 0.410 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 11653 | 0.410 |
Why?
|
| Remission Induction | 1 | 2016 | 2388 | 0.360 |
Why?
|
| Child | 25 | 2024 | 79623 | 0.350 |
Why?
|
| Nervous System Diseases | 2 | 2022 | 1645 | 0.340 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 691 | 0.330 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 1524 | 0.290 |
Why?
|
| Brain Diseases | 1 | 2016 | 1540 | 0.290 |
Why?
|
| Central Nervous System | 3 | 2022 | 1334 | 0.280 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 13621 | 0.260 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 5214 | 0.250 |
Why?
|
| Child, Preschool | 13 | 2023 | 41935 | 0.250 |
Why?
|
| Hodgkin Disease | 1 | 2012 | 1381 | 0.230 |
Why?
|
| Adolescent | 16 | 2024 | 87560 | 0.220 |
Why?
|
| Retrospective Studies | 14 | 2024 | 80121 | 0.210 |
Why?
|
| Young Adult | 14 | 2024 | 58483 | 0.210 |
Why?
|
| Histiocytic Disorders, Malignant | 1 | 2022 | 14 | 0.200 |
Why?
|
| Choriocarcinoma | 1 | 2022 | 121 | 0.200 |
Why?
|
| Neurosurgical Procedures | 1 | 2013 | 2052 | 0.200 |
Why?
|
| Brain Stem Neoplasms | 1 | 2024 | 190 | 0.200 |
Why?
|
| Prognosis | 6 | 2023 | 29561 | 0.190 |
Why?
|
| Gangliosides | 1 | 2021 | 132 | 0.180 |
Why?
|
| Isocitrate Dehydrogenase | 2 | 2023 | 922 | 0.170 |
Why?
|
| Infant | 8 | 2022 | 35941 | 0.150 |
Why?
|
| Teratoma | 1 | 2020 | 404 | 0.140 |
Why?
|
| Humans | 31 | 2024 | 759255 | 0.140 |
Why?
|
| Pathology, Molecular | 1 | 2019 | 330 | 0.140 |
Why?
|
| Treatment Failure | 1 | 2022 | 2642 | 0.130 |
Why?
|
| Mitoxantrone | 1 | 2016 | 149 | 0.130 |
Why?
|
| Radiotherapy Dosage | 2 | 2021 | 2895 | 0.130 |
Why?
|
| Methylene Blue | 1 | 2016 | 152 | 0.130 |
Why?
|
| Autopsy | 1 | 2019 | 1006 | 0.130 |
Why?
|
| Benzimidazoles | 1 | 2020 | 858 | 0.130 |
Why?
|
| Drug Resistance | 1 | 2021 | 1611 | 0.120 |
Why?
|
| Asparaginase | 1 | 2016 | 225 | 0.120 |
Why?
|
| Vinblastine | 1 | 2016 | 487 | 0.120 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 39216 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2022 | 5635 | 0.110 |
Why?
|
| Combined Modality Therapy | 2 | 2022 | 8549 | 0.110 |
Why?
|
| Adult | 13 | 2024 | 219390 | 0.110 |
Why?
|
| Antibodies | 1 | 2021 | 2423 | 0.110 |
Why?
|
| Male | 14 | 2022 | 358719 | 0.100 |
Why?
|
| Sarcoma | 1 | 2022 | 1786 | 0.090 |
Why?
|
| Female | 13 | 2022 | 390240 | 0.090 |
Why?
|
| Dacarbazine | 1 | 2013 | 560 | 0.090 |
Why?
|
| Nausea | 1 | 2013 | 675 | 0.090 |
Why?
|
| Vomiting | 1 | 2013 | 647 | 0.080 |
Why?
|
| Immunotherapy | 2 | 2024 | 4622 | 0.080 |
Why?
|
| Dexamethasone | 1 | 2016 | 1927 | 0.080 |
Why?
|
| Mutation | 5 | 2023 | 29877 | 0.080 |
Why?
|
| Medical Oncology | 1 | 2019 | 2311 | 0.070 |
Why?
|
| Glioblastoma | 1 | 2022 | 3482 | 0.070 |
Why?
|
| Genomics | 1 | 2023 | 5775 | 0.070 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 7003 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2021 | 9282 | 0.060 |
Why?
|
| Headache | 1 | 2013 | 1249 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2013 | 3519 | 0.060 |
Why?
|
| Recurrence | 1 | 2016 | 8469 | 0.060 |
Why?
|
| Immunologic Factors | 2 | 2024 | 1588 | 0.050 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2023 | 2052 | 0.050 |
Why?
|
| Off-Label Use | 1 | 2024 | 184 | 0.050 |
Why?
|
| Tryptophan | 1 | 2024 | 480 | 0.050 |
Why?
|
| Neurofibroma, Plexiform | 1 | 2020 | 66 | 0.040 |
Why?
|
| Pinealoma | 1 | 2020 | 51 | 0.040 |
Why?
|
| Ribonuclease III | 1 | 2022 | 278 | 0.040 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2021 | 303 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 642 | 0.040 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2022 | 383 | 0.040 |
Why?
|
| Basal Ganglia | 1 | 2021 | 549 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2022 | 54204 | 0.040 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2022 | 1078 | 0.040 |
Why?
|
| Endocytosis | 1 | 2021 | 960 | 0.030 |
Why?
|
| Oncogenes | 1 | 2022 | 1221 | 0.030 |
Why?
|
| Thalamus | 1 | 2021 | 1041 | 0.030 |
Why?
|
| Disease Progression | 2 | 2024 | 13479 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2022 | 1588 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 4111 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 2198 | 0.020 |
Why?
|
| Base Sequence | 1 | 2022 | 12450 | 0.020 |
Why?
|
| Time Factors | 1 | 2013 | 40109 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2020 | 64879 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2022 | 2803 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2021 | 5870 | 0.020 |
Why?
|
| Leukocytes | 1 | 2018 | 2030 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 20461 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 3615 | 0.020 |
Why?
|
| Neutrophils | 1 | 2021 | 3767 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2018 | 4000 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2022 | 8000 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 10827 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 36160 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 16871 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 9194 | 0.010 |
Why?
|
| Biomedical Research | 1 | 2019 | 3416 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 5247 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2018 | 26109 | 0.010 |
Why?
|
| Middle Aged | 2 | 2023 | 219653 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 13238 | 0.010 |
Why?
|
| United States | 1 | 2022 | 72237 | 0.010 |
Why?
|
| Aged | 1 | 2023 | 168617 | 0.010 |
Why?
|
Concepts
(120)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(42)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_